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Kinetic model for designing a cancer therapy
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Abstract
A kinetic model has been developed to study cancer growth. Cancer growth has been considered
as interaction between various independent but interacting compartments. The model considers
cell growth and metastasis resulting in the formation of new tumor masses. Using certain
representative parameter values, cell growth has been modeled in the absence and the presence of
various cancer therapies. Based on this analysis, the critical parameters involved in cancer
development have been identified. This model may thus be useful in studying and designing a cancer
therapy using the data obtained from specific in vitro experiments.
Background
Cancer has been a major area of research for several years
and information is now available about how tumor cells
evade the immune system of the body, and how they ef-
fectively get immortal. Chemo- and radio-therapies are
currently the main cancer therapies for treatment/ control
of the localized as well as invasive cancers. However, new
treatment strategies are being studied so that a safer and a
more effective cancer therapy may be developed. Recent
studies have shown that cancer cells in case of several can-
cer types show high Epidermal Growth Factor (EGF) re-
ceptor expression on their surface and this is responsible
for metastasis as well as self-induced proliferation. Besides
metastasis, cancer cells induce angiogenesis to obtain nu-
trition, and to ensure survival and ability to proliferate [1].
Based on these findings, attempts are being made to target
EGF and/ or VEGF (Vascular Endothelium Growth Factor)
receptors in order to reduce the rate of tumor progression,
and eventually stop the tumor cells from becoming can-
cerous. Studies have demonstrated reduced cell growth,
and degeneration of tumors upon treatment with anti-
EGF receptor antibodies [2]. However, most studies show
positive results in vitro but may fail to be equally effective
in vivo. This is possibly due to the interaction between dif-
ferent sub-systems of a body, which play a crucial role in
tumor growth and development of cancer but could not
be taken into account during in vitro experiments because
of the complexity of the system. Therefore, it is important
to relate the in vitro experiments to the in vivo situations to
be able to predict the efficacy of a treatment strategy.
Various models have been developed to study cancer de-
velopment and tumor growth [3–6]. Some of these mod-
els have studied the tumor growth before it becomes
invasive or during the early stages of invasion [3]; others
analyze the stages in tumor development [4]. Several
models are based on the spheroid model or other related
models to analyze the dynamics of antibody-drug therapy
[5,6]. These models consider the diffusion of an antibody-
drug into the tumor mass followed by the binding of the
antibody to the tumor cell, and subsequent internaliza-
tion of the antibody-drug complex. However, these mod-
els study the dynamics of an individual tumor without
considering the effect of other tumors growing simultane-
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whole is not considered. Thus, the previously developed
models give a microscopic picture, which may not be use-
ful in studying the efficacy and design of cancer therapies
as the therapies act on a macroscopic scale.
The kinetic modeling may be expected to be useful in the
identification of the critical parameters that should be tar-
getted in therapy. In addition to that, the requirement for
a combination therapy may also be revealed from the ki-
netic modeling of the complete system. This can make the
therapy more focussed and effective. In this paper, a kinet-
ic model based on interactions between different com-
partments of a body has been developed. Thus, the
kinetics of the process has been studied rather than the ki-
netics of a single entity. The model has thereafter been an-
alyzed using a set of representative parameter values to
demonstrate the utility and the applicability of this mod-
el. We have also shown how one can study and compare
various treatment strategies using the developed kinetic
model.
Kinetic model for cancer
Cancer starts with a tumor growth, which may be fol-
lowed by metastasis leading to spreading of the cancerous
cells in various regions of the body. These metastasizing
cells are carried away to the different regions through
bloodstream where they may attach to a tissue and prolif-
erate [1]. However, the tumor cells entering the blood-
stream may also be cleared through the body by the
immune system or any drug action, or death by apoptosis
due to the requirement of the cells to attach to the tissue
at a new site and adapt to the new environment [1]. Thus,
only a very small fraction of cells that escape from a pri-
mary tumor survive and initiate a new tumor. Cell death
and unsuccessful cell attachment are thus taken into ac-
count as plasma clearance in the model. Tranformed cells
are exchanged between a primary tumor and the plasma,
which have been treated as two interacting but independ-
ent compartments. The cells present in plasma may either
be cleared or may attach to another tissue and start grow-
ing into a new solid tumor. In order to model the cell
growth within solid tumors, population dynamics model
has been used, where T0 is the equilibrium tumor cell con-
centration in the tumor and r is the specific growth rate
[7,8]. However, in physiological situation, T0 may be var-
iable as the tumor cells are able to procure more nutrition
by carrying out angiogenesis (assuming no spatial limita-
tions for tumor growth). Thus,
dTtum/dt =  rTtum(1-Ttum/T0) -  kf1Ttum + kr1Tplas
 ...(1)
dTplas/dt =  kf1Ttum - kr1 Tplas + n. (- kf2Tplas +  kr2Tnew)
-  cTplas  ...(2)
dTnew/dt =  rTnew(1 - Tnew/T0) + kf2Tplas -  kr2Tnew
 ...(3)
where,
Ttum = Cell concentration of the original tumor
Tplas = Cancer cell concentration in the plasma
Tnew = Cell concentration of new and developing tumor
n = Number of new tumors being developed simultane-
ously
and all kf's and kr's are the corresponding rate constants of
the steps shown in Figure 1. All equations take into ac-
count the cell growth, loss into plasma due to metastasis,
and attachment of the cells from plasma to the tissue. In
the model, , , and  are the relative drug efficacy factors
depending on the therapy and its efficacy. These factors
represent the effect a specific cancer therapy has on the dif-
ferent parameters. In the absence of any therapy, these fac-
tors are all equal to unity as the values are relative to the
case when no therapy is being applied.
This model, therefore describes tumor mass growth and
associated metastasis. Depending on the parameter val-
ues, tumor growth in various stages may be studied. For
example, by choosing the parameter values for the devel-
oping tumor, we can consider the initial stages when it
Figure 1
Kinetic scheme depicting interaction between various com-
partments resulting in cancer growth. Three compartments
have been considered- primary tumor, secondary tumor, and
the plasma. The tumor cells are constantly exchanged
between these compartments. Moreover, cells are cleared
out by means of immune response and apoptosis due to the
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centration, the parameter values may be changed to incor-
porate metastasis. In fact, once the new tumor has
sufficient cell concentration, it can itself be considered as
a source tumor and the cancer cell growth reanalyzed. On
the other hand, the parameters may be chosen assuming
that the tumor cells are constantly metastasizing. This as-
sumption may be valid if the cell concentration limit for
the cell to start metastasizing is orders of magnitude less
than the steady state concentration it attains. Thus, this ki-
netic model is of a very general nature and a simplified
form of the physiological situation, as there exists a far
greater interaction between different compartments than
what has been modeled. Similar compartmentalized
model has previously been successfully applied to model
HIV-infected patients [8].
Simulation of cancer growth and development
To study the dynamics of cancer growth, we have used cer-
tain representative values for the model parameters as tab-
ulated in Table 1. All simulations have been carried out
using Mathematica 4 (Wolfram Research). In the graphs
thus obtained, we have plotted Ttum and Tnew as a func-
tion of time. This is important as during drug treatment or
any other therapy, it is useful to know the concentration
profile as a function of time such that different therapies
my be compared.
For the simulation of the cancer growth, the drug efficacy
parameters have all been taken as one in the absence of
any cancer therapy, as mentioned earlier. However, de-
pending on the therapy, different values of , , and 
have been taken. The values of the drug efficacy parame-
ters are shown in Table 2.
The parameter values are mostly based on some experi-
mental observations for various cancer types. We have tak-
en the potential doubling time (Tpot) for the (human)
tumor mass under consideration as ten days [9], though
some tumors may have a slower growth rate. It is known
that metastasis reduces the effective doubling time such
that the observed doubling time may be few weeks to few
months [10]. Incorporating this information, we obtain
the rate constant for metastasis for our model (kf1 and
kr2). For the analysis, we have assumed metastasis to be a
continuously occurring process. Since, cells are unable to
attach to the endothelial tissue easily, the rate constants
for attachment of cells to the existing tumor or to a new
tumor has been taken as nearly 1% of the rate of metasta-
sis. Based on a metastasis experiment done in mouse
model [11], the initial conditions for the simulations as
well as the rate of plasma clearance have been chosen. In
the experiments that have been previously carried out
[11,12], a primary tumor was developed, which has been
assumed to have a cell concentration of 3  106 cells/ ml
based on in vitro studies [12] as well as the number of cells
implanted in the mouse model [11]. Thereafter, 2  105
tumor cells were injected into vein, and metastasis of the
tumor cells was observed [11]. Assuming that tumor cells
injected into the plasma at the beginning of the experi-
ment correspond to the steady state cell concentration in
the plasma, the rate constant for plasma clearance has
been obtained. This may be valid due to the fact that the
plasma volume is large, tumors may be localized or may
not invade several tissues, and eventually steady state is
reached so that the cells released by existing tumor either
result in new tumors or are cleared out from the body.
These factors result in the cell concentration in the plasma
remaining nearly constant throughout.
The variation in cell concentrations in the existing tumor,
and the developing tumor in the absence of any cancer
therapy has been shown in Figure 2(a). Different therapies
considered are reduction in cell growth as well as metasta-
sis by EGF receptor inhibitors [2,13,14], and reduction in
specific growth rate and increase in clearance rate by acti-
vating immune response against cancer cells using thera-
pies like adoptive therapy [15–22]. Figures 2(b) and 2(c)
depict the cell growth in the presence of the two drug ther-
apies- EGFR inhibitors and adoptive therapy respectively.
Results and discussion
Cell growth in the absence of any cancer therapy has been
depicted in Figure 2(a). The existing tumor cells grow and
attains a steady-state concentration. At the same time, the
tumor cells escape from the primary tumor and form a
secondary tumor at a new site. Eventually, both the prima-
ry as well as the secondary tumors reach the same steady
state cell concentration. This sigmoidal trend has previ-
ously been observed for tumor growth [7,12]. Thereafter,
the primary and the secondary tumors can result in forma-
tion of new tumors, and thus the cancer spreads to various
regions of the body.




T0 3  106 cells/ml
kf1 6.7  10-2 day-1
kr1 6.7  10-4 day-1
kf2 6.7  10-4 day-1
kr2 6.7  10-2 day-1
c 0.67 day-1
n 10Page 3 of 6
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specific growth rate (r) and rate of metastasis (kf1 and kr2)
decrease, and this subsequently results in slower tumor
growth of the existing as well as the developing tumors
(Figure 2(b)). However, unless the inhibitor efficacy is
sufficient enough to decrease the rate of cell growth to less
than the rate of cell clearance from plasma, cancer cells
cannot be eradicated from the body and the effect is mere-
ly to delay the cell growth (which in this case is by a factor
of ~4). This extension may be helpful if there is any sub-
sequent and/ or parallel treatment. The reduction in the
cell release rate may in fact result in higher steady state cell
concentration in the primary tumor thereby, partially or
totally overcoming the effect of the reduction in the cell
Figure 2
Growth of existing tumor and new tumor: a) in the absence of any therapy; b) EGFR inhibitor therapy; c) adoptive therapy; and
d) antibody-drug therapy. A single tumor leading to multiple tumors has been considered for analysis. The same analysis may be
applied to all the existing tumors at any given time to study the kinetics of cancer progression in the absence and the presence
of various cancer therapies.
Table 2: Drug efficacy parameters for simulating different cancer therapies
Parameter EGFR inhibitor therapy Adoptive therapy Antibody therapy
 0.2 0.2 0.2
 0.2 1 1
 1 5 1Page 4 of 6
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apy is combined with other treatment(s) that can further
reduce the rate of cell growth, then tumor degeneration
may be observed.
In contrast to anti-EGFR treatment, the model predicts
that the adoptive therapy may lead to a nearly complete
elimination of new as well as existing tumors. The param-
eters affected by adoptive therapy are r and c, i.e. rate of
cell growth decreases and rate of plasma clearance of cells
increases, as the immune response destroys the tumor
cells in the tumor masses as well as in the plasma. As seen
in Figure 2(c), a small reduction in specific rate of cell
growth and an increase in plasma clearance can result in
complete removal of cancer cells from existing tumors in
a matter of few months and it also ensures that the new tu-
mor masses are not able to reach the high concentrations.
These new tumor masses also degenerate progressively
and thus, the cancerous cells are completely eliminated in
a few months. Since, this form of treatment is relatively
fast compared to any combination therapy involving
EGFR inhibitor therapy, this may even be used for cancers
in advanced stages. However, activation of immune re-
sponse against cancer cells itself is a big challenge. This is
so because cancer cells are able to escape immune surveil-
lance by shedding the antigen peptides on their surfaces,
and by releasing blocking factors, which can neutralize
the NK cells [22,24]. In this direction, various strategies
are being explored like adoptive therapy, dendritic cell
vaccine and enhancement of NK cell activity through IL-2
[25]. One way to overcome this limitation is to activate an
immune response against the blocking factors themselves.
In that way, all the blocking factors may be neutralized so
that the TNF/ IL-1 [26] or NK [27] can destroy the cancer
cells in the tumor as well as in the plasma. After activating
the immune response against the blocking factors, NK cell
activity may be enhanced by priming them with IL-2 de-
pending on the state of cancer and the NK cell activity.
Lastly, therapies like antibody therapy with antibody-drug
targeted against the cancer cells, and anti-angiogenesis
therapy decrease the rate of cell growth keeping rate con-
stant for cell release from the tumor unchanged. In that
case, tumor degeneration is observed (Figure 2(d)). This
may be explained by the fact that the balance between cell
growth and cell clearance is disturbed and this may result
in smaller tumors and/or eradication of tumor masses.
The degeneration of tumor mass with antibody therapy
assumes that the antibody is accessible to all the tumor
cells, which is not the case in physiological situation.
In this way, we observe that cancer growth can be mod-
eled by considering the cell growth and metastasis as in-
teraction between various compartments. Using this
model, various cancer therapies may be compared for
their efficacies, and may be focussed to result in a better
and an effective therapy. However, we would like to point
out that these results are based on the parameter values se-
lected for the analysis and therefore, the true efficacy of a
therapy can be realized only after carrying out analysis
with the corresponding parameter values. In addition, the
results depend on the efficacy of a therapy, i.e. the values
of the drug efficacy factors determine the efficacy of a ther-
apy. The actual effect of any therapy will depend on the
drug efficacy parameters but from this analysis, we infer
that the reduction in specific growth rate of cells is prima-
ry, and the rate of cell release from the tumor masses
should not be decreased substantially for the success of
the treatment strategy. Thus, these results should not be
taken as a means to accept or reject a therapy, but should
rather be used for improving and designing the cancer
therapies.
Summary
Cancer growth has been modeled as the growth as an ex-
isting tumor and metastasis resulting in interaction be-
tween the existing tumor and plasma viewed as two
independent but interacting compartments. The cells
present in plasma, thereafter attach to another tissue and
grow into a new tumor mass. The new tumor mass in-
creases in size due to cell growth and cell uptake from
plasma. However, once the cell concentration reaches a
steady state concentration, this tumor mass also becomes
a source for new tumor masses, i.e. it forms another stage
for cancer growth. Further, two different cancer therapies-
EGFR inhibitor therapy and adoptive therapy- were ana-
lyzed using this kinetic model. The results point to the im-
portance of targeting the specific growth rate as well as the
plasma clearance rate in the system. Thus, this model
helps study the efficacy of the cancer treatment therapies,
and also helps determine the critical factors, which may
be targeted. However, these results are strongly dependent
on the parameter values, which should be appropriately
taken and analyzed for specific case; but this model is use-
ful in focussing and improving a cancer therapy in order
to make it more effective.
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